Robert R. McWilliams

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Tables 1 - 9 from Genes–Environment Interactions in Obesity- and Diabetes-Associated Pancreatic Cancer: A GWAS Data Analysis

  2026-06-17

• Supplementary Methods from Genes–Environment Interactions in Obesity- and Diabetes-Associated Pancreatic Cancer: A GWAS Data Analysis

  2026-06-17

• Data from Genes–Environment Interactions in Obesity- and Diabetes-Associated Pancreatic Cancer: A GWAS Data Analysis

  2026-06-17

• Real-world comparison of ipilimumab–nivolumab dosing strategies in melanoma brain metastases.

  Journal of Clinical Oncology · 2026-05-28

• Incidence, severity, and management of severe adverse events in first-line (1L) treatments for metastatic pancreatic ductal adenocarcinoma (mPDAC): A retrospective observational study.

  Journal of Clinical Oncology · 2026-05-28

• Abstract 2611: Prospective evaluation of 68Ga-PSMA PET imaging in advanced hepatocellular carcinoma patients undergoing first line immunotherapy.

  Cancer Research · 2026-04-03

• Abstract 2107: Genomic landscape of melanoma brain metastases: Real-world analysis and comparison with public melanoma cohorts.

  Cancer Research · 2026-04-03

• Abstract 3706: Impact of number of IL-2 infusions and product out of specification status on outcomes of tumor infiltrating lymphocyte therapy for melanoma

  Cancer Research · 2026-04-03

• Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).

  Journal of Clinical Oncology · 2026-01-10

• Impact of infusion timing (IT) on survival outcomes across gastrointestinal (GI) malignancies: A multicenter analysis of circadian rhythm (CR) effects on immune checkpoint inhibitor (ICI) activity.

  Journal of Clinical Oncology · 2026-01-10

• Supplementary Methods and Tables 1-3 from Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives

  2025-12-17

• Supplementary Table S5 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

  2025-11-25

• Supplementary Table S4 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

  2025-11-25

• Supplementary Table S2 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

  2025-11-25

• Supplementary Table S3 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

  2025-11-25

• Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

  2025-11-25

• Supplementary Figure S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

  2025-11-25

• Supplementary Table S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

  2025-11-25

• Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

  2025-11-25

• Optimized dose schedule of rucaparib and liposomal irinotecan/5‐fluorouracil in metastatic gastrointestinal cancers: A phase 1 study

  Cancer · 2025-11-22 · 1 citations